Copyright
©The Author(s) 2022.
World J Clin Oncol. Apr 24, 2022; 13(4): 267-275
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.267
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.267
Table 3 Comparison of safety and efficacy of frontline Nivolumab + Ipilimumab vs chemotherapy in malignant pleural mesothelioma
| Clinical trial | Phase | Treatment arm | mOS | mPFS | ORR | AEs G3 | ||
| CheckMate-743[35] | III (open-label) | Nivolumab 3 mg/kg every 2 wk + Ipilimumab 1 mg/kg every 6 wk | 18.1 mo | HR: 0.74, P = 0.002 | 6.8 mo | HR: 1.00 | 32% | 30% |
| Cisplatin + Pemetrexed | 14.1 mo | 7.6 mo | 8% | 32% | ||||
| EMPHACIS[5] | III (single blind) | Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 | 12.1 mo | HR: 0.77, P = 0.002 | 5.7 mo | HR: 0.68, P = 0.001 | 41.3% vs 16.7% (P < 0.001) | |
| Cisplatin 75 mg/m2 | 9.3 mo | 3.9 mo | 16.7% | |||||
| MAPS[12] | III (open-label) | Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 with 15 mg/kg Bevacizumab in | 18.8 mo | HR: 0.77, P = 0.0167 | 9.2 mo | HR: 0.61, P < 0.0001 | NR | 71% |
| Pemetrexed 500 mg/m2 + Cisplatin 75 mg/m2 | 16.1 mo | 7.3 mo | 62% | |||||
- Citation: Mielgo-Rubio X, Cardeña Gutiérrez A, Sotelo Peña V, Sánchez Becerra MV, González López AM, Rosero A, Trujillo-Reyes JC, Couñago F. Tsunami of immunotherapy reaches mesothelioma. World J Clin Oncol 2022; 13(4): 267-275
- URL: https://www.wjgnet.com/2218-4333/full/v13/i4/267.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i4.267